Mixed Results for Immunotherapy in Metastatic Prostate Cancer

[snoraste]

"Ten of 35 (28.6%) patients responded to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy). The activity fell short of the 40% threshold for a positive outcome but well above the historical response rate for immunotherapy in patients previously treated with docetaxel."

"In analysis of response by type of biomarker, four of five patients with dMMR responded, as well as three of four with BRCA1/2 mutations, and two of 10 with high inflammatory infiltrate (including one patient with CDK12 aberrations in addition to increased inflammatory infiltrate). No responses were observed in the remaining six patients with CDK12 alterations, eight with ATM alterations, two with CHD1 alterations, or one with CHEK2 alterations."

medpagetoday.com/meetingcov...

[addicted2cycling]

Another try >>>

cancerres.aacrjournals.org/...

[snoraste in reply to addicted2cycling]

very promising. From Aug2020, I don't see any follow up on that. surprising.

[p3d1]

You would think that they would test with a group of patients with Brca1/2 and see results of 75%. A no brainer for approval.

[Rexwayne]

I did a couple of different immunotherapy. One being Provenge and I can’t remember the 2nd one. Both slowed it down but did not stop the cancer. I have metastatic prostate cancer. Each bought me time 9 months to a year. It was 6 months of treatments and 6 months of enjoying no treatments. It’s been 5 years since the first round of immunotherapy I have also completed RU 223, chemo and radiation treatments. It’s been a tough road but I’m still here and my numbers are looking good. I know someone who had a very bad reaction to immunotherapy and died within a month of starting it. You need to decide what’s best for you and remember Everyone is different and you may not have the same outcome as others